Consumers filed over 200 complaints with some telemedicine companies for misleading customers about costs of weight loss using GLP-1 drugs.

Viking Therapeutics has progressed its obesity treatment program, centered on the drug candidate VK2735, into the pivotal Phase 3 stage of development. The comp ...